-
Sector Analysis
NewHER2-Positive Breast Cancer Epidemiology Analysis and Forecast to 2033
HER2+/HR+ Breast Cancer Report Overview In the 8MM, there were 107,352 diagnosed incident cases of invasive HER2+/HR+ breast cancer in 2023. The diagnosed incident cases of invasive HER2+/HR+ breast cancer will register an AGR of more than 1% during 2023-2033. HER2+/HR+ Breast Cancer Market Outlook, 2023-2033 (Diagnosed Incident Cases) Buy the Full Report for More Insights into the HER2+/HR+ Breast Cancer Market Forecast Download a Free Report Sample The HER2+/HR+ breast cancer market research report provides an overview of the...
-
Product Insights
NewMycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Mycosis Fungoides Clinical Trial Report Overview A total of 328 mycosis fungoides clinical trials were conducted as of April 2024. The mycosis fungoides clinical trial report provides a comprehensive understanding of the mycosis fungoides clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · North America · ...
-
Product Insights
NewChronic Lymphocytic Leukemia (CLL) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Chronic Lymphocytic Leukemia (CLL) Clinical Trial Report Overview A total of 2311 CLL clinical trials were conducted as of April 2024. The CLL clinical trial report provides a comprehensive understanding of the CLL clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · Europe...
-
Product Insights
Ewing Sarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Ewing Sarcoma Clinical Trial Report Overview A total of 434 Ewing Sarcoma clinical trials were conducted as of February 2024. The Ewing Sarcoma clinical trial report provides a comprehensive understanding of the Ewing Sarcoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · North America · ...
-
Product Insights
Glioblastoma Multiforme (GBM) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Glioblastoma Multiforme (GBM) Clinical Trial Report Overview A total of 2,375 Glioblastoma Multiforme (GBM) clinical trials were conducted as of February 2024. The GBM clinical trial report provides a comprehensive understanding of the GBM clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe...
-
Product Insights
Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
HER2 Negative Breast Cancer Clinical Trial Analysis Report Overview A total of 2,230 HER2- breast cancer clinical trials were conducted as of February 2024. The HER2- breast cancer clinical trial report provides a comprehensive understanding of the human epidermal growth factor receptor 2 negative breast cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the...
-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · ...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Antibody drug conjugates(ADC) cancer therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Antibody drug conjugates(ADC) cancer therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Approximately 90% of ovarian cancer cases are epithelial, with distinct sites of origin arising from the ovarian surface epithelium or distal fallopian...